Hims & Hers Health, Inc. Class A Common Stock (HIMS)
45.67
+3.79 (9.05%)
NYSE · Last Trade: May 6th, 10:43 AM EDT
Detailed Quote
Previous Close
41.88
Open
38.33
Bid
45.60
Ask
45.68
Day's Range
38.21 - 48.52
52 Week Range
11.45 - 72.98
Volume
63,250,247
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
33,131,307
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
Telehealth company Hims & Hers Health (NYSE:HIMS) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 111% year on year to $586 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $540 million was less impressive, coming in 4.3% below expectations. Its GAAP profit of $0.20 per share was 66.4% above analysts’ consensus estimates.
Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2025, in a shareholder letter that is posted at investors.hims.com.
Hims & Hers Health shares are trading marginally lower Monday morning. The company earlier appointed Nader Kabbani as its new Chief Operations Officer, ahead of Q1 results.
Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to expand into other healthcare areas.
A nearly 20-year Amazon veteran, Nader Kabbani said he was drawn to Hims & Hers by its potential to expand access to fast, reliable, and high-quality care.
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Nader Kabbani as Chief Operations Officer.1 A seasoned executive known for scaling trusted consumer and healthcare logistics businesses, Kabbani will oversee operations as the company expands access to personalized care for millions more individuals.
Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease affecting patients with obesity.
Needham called the tie-up a “groundbreaking partnership” and said it alleviates investor concerns around Hims’ ability to hit its 2025 weight loss revenue guidance.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 34.9% in the pre-market session after Novo Nordisk announced plans to offer its weight loss drug Wegovy through the company's (Hims & Hers Health's) platform, expanding access to one of its fastest-growing products. By partnering with a popular telehealth company, Novo could speed up Wegovy's adoption, leading to more prescriptions. For investors, the deal signals a clear strategy to expand distribution and grab more market share, a move that could also boost sales growth for Hims & Hers (HIMS).
